We are excited to announce that Zepto Life has officially started a pilot clinical study in collaboration with Mayo Clinic to evaluate our breakthrough diagnostic test for invasive fungal infections. This study represents a critical step forward in our mission to improve diagnostics and patient outcomes worldwide.
Led by Dr. Vergidis from Mayo Clinic, this pilot study will focus on assessing the efficacy of Zepto’s Fungiflex test, which aims to provide clinicians with a powerful tool to detect invasive fungal infections directly from patient blood samples. These infections, often difficult to diagnose, can lead to severe complications if not identified early. Our collaboration with Mayo Clinic underscores the importance of advancing diagnostic tools that can make a meaningful impact on patient outcomes.
About Zepto Life Technology
Founded in 2014, Zepto Life Technology is a privately held company based in St. Paul, Minnesota. We are at the forefront of developing groundbreaking products that can detect invasive fungal infections using cell-free DNA found in blood. Our cutting-edge detection technology, Giant Magneto Resistance (GMR), is renowned for its high sensitivity and specificity. This Nobel Prize-winning technology from 2007 enables us to detect multiple infections accurately without compromising specificity.
In collaboration with Mayo Clinic, Zepto Life Technology is committed to advancing healthcare by providing precise and reliable diagnostic solutions.